arGEN-X advances a third therapeutic antibody program into preclinical development: http://t.co/hBB8aUOQ
posted 17 hours ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development. read more
Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. read more
TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the second cohort of the company's Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit and dose the remaining 20 patients of this cohort and to open the third and final cohort. The Phase IIa trial is based on a three-step dose-finding protocol, where each step starts with a safety review of the first three patients after 40 days of dosing. read more
Study confirms benefits of ChondroCelect in daily practice, significantly expands data set, and underpins commercial potential. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole. read more
Galapagos NV (Euronext: GLPG) announced today that it has initiated clinical Phase I development of the first inhibitor of GPR43, a novel target for inflammatory diseases. This target was identified through Galapagos' proprietary target discovery platform. read more
TiGenix (NYSE Euronext: TIG) announced today that it has obtained all the required approvals to start the company's Phase I clinical trial to assess the safety of intra-lymphatic administration of its expanded adipose stem cells product (Cx621). The Phase I will enroll 10 healthy volunteers and the company expects the last volunteer to be dosed in April, with final results reported by June 2012. Cx621 aims to capitalize on the benefits of TiGenix's proprietary approach of intra-lymphatic administration to treat autoimmune disorders. read more
Galapagos NV (Euronext: GLPG) announced today that investigational medicine GLPG0778, which is part of its immuno-inflammatory alliance with GlaxoSmithKline, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers. The study also provided information on the safety and pharmacokinetic (PK) profile of GLPG0778. read more
ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. The trial has recruited patients from 36 centers across Europe. read more
